ELMMB logo
Facebook logo Twitter logo
Menu

7.3 Contraceptives

7.3 Contraceptives


      7.3.1 Combined hormonal contraceptives
      CSM advice - provided that women are fully informed of the small risks of venous thromboembolism and do not have medical 
      contraindications, it should be a matter of clinical judgement and personal    choice which type of oral contraceptive should be 
      prescribed.
 
        Group 1 - First line 
        The cheapest and safest in terms of VTE risk
        GREEN      Brevinor®/ Ovysmen®(ethinyloestradiol 35mcg/norethisterone 500mcg) 
        GREEN      Microgynon 30®/Ovranette® (ethinyloestradiol 30mcg/ levonorgestrel 150mcg)  
 
        Group 2 - Second line 
        May be useful if acne or other androgenic side effects are problematical with the first line choice of pill.
        GREEN      *Cilique®(ethinyloestradiol 35mcg/ norgestimate 250mcg)  *[alternative to Cilest® - discontinued from July 2019]
        GREEN      Femodene® (ethinyloestradiol 30 mcg/ gestodene 75mcg)   
        GREEN      Marvelon®(ethinyloestradiol 30mcg/desogestrel 150mcg)   
 
        Group 3 – Second line 
        This pill with lower oestrogen content (20micrograms) may be useful if nausea, breast tenderness or general headache (not 
        migraine)  are problematical with the first line choice of pill.  
        GREEN      Mercilon® (ethinyloestradiol 20mcg/desogestrel 150mcg)    
 
        Group 4 - Second line 
        Useful alternatives for breakthrough bleeding when other causes excluded.
        GREEN      Loestrin 30® (ethinyloestradiol 30mcg/ norethisterone 1.5mg)     
        GREEN      Norimin® tablets (ethinyloestradiol 35mcg/ norethisterone 1mg)      
 
        Note: Everyday pills (eg MicrogynonED®) (21 active tablets followed by 7 inactive tablets) may be useful for women who find 
                   it difficult to remember to restart after the pill free week.
 
        Group 5 - Third line 
        For women with acne, not settling with two previously tried second line pills.
        GREEN       Yiznell® tablets (ethinylestradiol 30mcg/ drospirenone 3mg)     
        GREEN       Lucette® tablets (ethinylestradiol 30mcg/ drospirenone 3mg) 
        GREEN       Yacella® tablets (ethinylestradiol 30mcg/ drospirenone 3mg)
 
        Interactions with liver enzyme inducing drugs
        Faculty advice relating to a long term course of an enzyme inducing drug in women unable to use an alternative method of 
        contraception is to use two low dose COCs providing a total daily dose of 50-60 micrograms of ethinyloestradiol (for example 
        two Microgynon 30® daily - unlicensed). Women are advised to use additional contraception, such as condoms during use of a 
        liver enzyme inducing drug and for 28 days after the liver enzyme-inducer is stopped.
 
        Low Strength Transdermal 
        Evra® is not recommended for routine use, but only for younger, or less compliant women, or those with GI disturbance 
        whilst taking oral contraceptives.
        GREEN      Evra® transdermal patch 
                          (ethinylestradiol 20micrograms/24hrs, norelgestromin 150micrograms/24hrs) 
 
        Biphasic/triphasic pills have no advantage over monophasic pills and are not listed.


      7.3.2 Progestogen-only contraceptives 
      These are useful for women in whom oestrogen is contraindicated or if breastfeeding.
 
          7.3.2.1 Oral progestogen-only contraceptives
          GREEN      Micronor® / Noriday® (norethisterone 350mcg)   
          GREEN      Norgeston® (levonorgestrel 30mcg) 
          GREEN      Desogestrel 75 microgram
 
          Desogestrel should not routinely be used as an alternative to COCs but is reserved for women who have problems adhering 
          to the 3 hour window for other oral progestogen only contraceptives. (Desogestrel can be taken up to 12 hours overdue)  
 
          7.3.2.2 Parenteral progestogen-only contraceptives
          For IUS/IUD and Implanon fitting special training is required (primary care -see nGMS enhanced services contract for details 
          and contact local CCG for further information as necessary). NICE guidance states that these methods together with Depo-       
          Provera® arethe most cost effective option and that their use should be encouraged.
 
          The CSM have also advised that; 
               >     In adolescents, medroxyprogesterone acetate (Depo-Provera®be used only when other methods of contraception 
                      are inappropriate 
               >     In all women, benefits of using medroxyprogesterone acetate beyond 2 years should be evaluated against risks; 
               >     In women with risk factors for osteoporosis an alternative method of contraception instead of medroxyprogesterone
                      acetate should be considered 
 
          GREEN      Medroxyprogesterone depot injection 150mg/1ml (Depo-provera®)
          GREEN      Medroxyprogesterone suspension for injection 104mg/0.65ml (Sayana® Press)
 
          The following are to be implanted by specially trained individuals only: 
          GREEN      Etonogestrel 68mg implantable rod (Nexplanon®) 
 
          7.3.2.3 Intra-uterine progesterone-only device 
            To be implanted by specially trained individuals only 
            GREEN      Levonorgestrel 20micrograms/24hrs intra-uterine system (Mirena®) 
            GREEN      Levonorgestrel 13.5 mg intra-uterine system (Jaydess®▼)   
 
             (contraceptive for up to 3 years, second line to Mirena®, only for women who want periods or if  there are problems 
             insterting Mirena®)
 
        7.3.5 Emergency contraception 
        GREEN      Levonelle® (levonorgestrel 1500microgram) 
 

 Back to Main Page
 
 

All material in this section is aimed at health care professionals, but is information currently held in the public domain, members of the
 public seeking advice on medicine-related matters are advised to speak with their GP, pharmacist, nurse or contact NHS111 Service 
  Email: info.elmmb@nhs.net
 Copyright© 2016 - 2023East Lancashire Medicines Management Board 
 All rights reserved.  Disclaimer/Terms and conditions